One-Year Outcomes of the Multi-Center StudY to Transplant Hepatitis C-InfeCted kidneys (MYTHIC) Trial

One-Year Outcomes of the Multi-Center StudY to Transplant Hepatitis C-InfeCted kidneys (MYTHIC) Trial

Introduction: Transplanting kidneys from hepatitis C virus (HCV) viremic donors into HCV-negative patients (HCV D-RNA-positive/R-negative) has evolved from experimental to “standard-of-care” at many centers. Nevertheless, most data derive from single centers and provide only short-term follow-up. Me...

Full description

Bibliographic Details
Main Authors: Meghan Elizabeth Sise, David Seth Goldberg, Douglas Earl Schaubel, Robert J. Fontana, Jens J. Kort, Rita R. Alloway, Christine M. Durand, Emily A. Blumberg, E. Steve Woodle, Kenneth E. Sherman, Robert S. Brown, Jr., John J. Friedewald, Niraj M. Desai, Samuel T. Sultan, Josh Levitsky, Meghan D. Lee, Ian A. Strohbehn, J. Richard Landis, Melissa Fernando, Jenna L. Gustafson, Raymond T. Chung, Peter Philip Reese
Format: Article
Language:English
Published: Elsevier 2022-02-01
Series:Kidney International Reports
Subjects:
cytomegalovirus infection
direct-acting antivirals
glecaprevir/pibrentasvir
hepatitis C virus
kidney transplantation
organ allocation
Online Access:http://www.sciencedirect.com/science/article/pii/S246802492101545X

Internet

http://www.sciencedirect.com/science/article/pii/S246802492101545X

Similar Items